Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.49 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25840370 | 1.00 | SCN1A (0.49) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL25840372 | 1.00 | SCN1A (0.49) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL9917364 | 0.95 | HRH3 (0.47) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL9917362 | 0.95 | HRH3 (0.47) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL25718340 | 0.84 | HRH3 (0.43) | HRH3 | |
| SCHEMBL9917363 | 0.84 | HRH3 (0.43) | HRH3 | |
| SCHEMBL9917361 | 0.84 | HRH3 (0.43) | HRH3 | |
| SCHEMBL13541811 | 0.82 | HRH3 (0.36) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL13541806 | 0.82 | HRH3 (0.36) | SCN1ASCN2ASCN3AHRH3MAOB | |
| SCHEMBL10192095 | 0.81 | SCN1A (0.52) | SCN1ASCN2ASCN3AHRH3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | AEOVIAN PHARMACEUTICALS, INC. | 2023-10-19 | — | — | US | disclosed |
| US-11702429-B2 | mTORC modulators and uses thereof | AEOVIAN PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702429-B2 | mTORC modulators and uses thereof | MTOR, RICTOR, RPTOR | SCN1A 4580/4885SCN2A 4077/4885SCN3A 4620/4885 |
| US-20230331737-A1 | MTORC1 MODULATORS AND USES THEREOF | MTOR, RPTOR, RICTOR | SCN1A 3057/4885SCN2A 3096/4885SCN3A 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.